 | | Vol. 14.15 – 29 April, 2022 |
| |
|
|
| Scientists suggested that the peripheral nervous system may have directly interacted with diseased arteries. Widespread neuroimmune cardiovascular interfaces arose in mice and human atherosclerosis-diseased adventitia segments showed expanded axon networks.
[Nature] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers showed that maladaptive bone marrow-mediated trained innate immunity underlied inflammatory comorbidities, as exemplified by the periodontitis-arthritis axis.
[Cell] |
|
|
|
| The authors developed an MG1 peptide and RVG29 peptide engineered nanoerythrocyte that could reprogram microglia from classical M1 toward alternative M2 by inducing heme oxygenase-1, stimulating Notch1/Hes1/Stat3 signaling, and further inhibiting NF-κB p65 translocation.
[Advanced Materials] |
|
|
|
| Scientists investigated transcriptional and epigenetic changes after acute, periodic and persistent IL-2 receptor signaling in mouse peripheral regulatory T cells in vivo using IL-2 or the long-acting IL-2-based biologic mouse IL-2–CD25.
[Nature Immunology] |
|
|
|
| Investigators used mouse models of DOCA+salt treatment and adoptive transfer of CD8+ T cells (CD8T) from hypertensive animals to normotensive animals in in vivo studies.
[Circulation Research] |
|
|
|
| Researchers reported that the LynB splice variant of the Src-family kinase Lyn exerted a dominant immunosuppressive function in vivo, whereas the LynA isoform was uniquely required to restrain autoimmunity in female mice.
[Science Immunology] |
|
|
|
| Scientists used an in vitro differentiation system and human skin–grafted mice to study memory T cell generation from circulating human memory T cell subsets.
[Science Immunology] |
|
|
|
| The authors showed that negative elongation factor (NELF), an RNA polymerase II pausing factor, cooperated with T cell factor 1 in T cell responses to cancer.
[Nature Communications] |
|
|
|
| Investigators showed that the strength of T cell receptor signaling controlled the requirement for interleukin-2 (IL-2) signals to form a pool of memory CD8+ T cells that competitively re-expanded upon secondary antigen encounter.
[Nature Communications] |
|
|
|
| Scientists found that combined oral FAK inhibitor plus function-blocking TIGIT antibody immunotherapy reduced tumor burden, prolonged mouse survival, and led to immune cell activation and tertiary lymphoid structure formation, hallmarks of an antitumor immune response.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Using single-cell transcriptomic analysis, researchers found that several CD4+ T-cell subsets were present in the intestines of colitic mice, including an interferon (IFN)-γ-producing subset.
[Cellular & Molecular Immunology] |
|
|
|
| Investigators showed that expression of Vav1-Myo1f, a recurrent peripheral T cell lymphoma-associated VAV1 fusion, induces oncogenic transformation of CD4+ T cells.
[Cell Reports] |
|
|
|
| The authors characterized islet antigen-specific T cells in non-obese diabetic mice lacking all three interferon receptor genes.
[Cell Reports] |
|
|
|
|
| Investigators discuss the current understanding of the multiple roles of TCF-1 in T cell development and function and their mechanistic underpinnings.
[Nature Immunology] |
|
|
|
| The authors discuss how extracellular, de novo synthesized and membrane lipids orchestrate T cell biology and describe the roles of lipids as regulators of intracellular signaling at the levels of transcriptional, epigenetic and post-translational regulation in T cells.
[Nature Chemical Biology] |
|
|
|
| Scientists discuss the interaction between macrophages and ferroptosis concerning three metabolisms and integrate the application of certain relationship in curing diseases, mostly cancer.
[Cell Death & Disease] |
|
|
|
|
| Applied Molecular Transport, Inc. announced positive top-line Phase II results from the FILLMORE monotherapy trial for AMT-101 in patients with chronic pouchitis, an orphan indication with significant unmet medical need and no current FDA-approved therapies.
[Applied Molecular Transport, Inc.] |
|
|
|
|
| May 30 – June 1, 2022
Brisbane, Queensland, Australia |
|
|
|
|
|
| | New York University College of Dentistry – New York, New York, United States |
|
|
|
| | The Pirbright Institute – Pirbright, England, United Kingdom |
|
|
|
| | Francis Crick Institute – London, England, United Kingdom |
|
|
|
| | Uppsala University – Uppsala, Sweden |
|
|
|
| | Fred Hutchinson Cancer Center – Seattle, Washington, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
